Trovagene announces completion of first dosing cohort of patients in phase 1b/2 trial
Trovagene announced completion of the first dose cohort in its Phase 1b/2 clinical trial of PCM-075, a highly-selective Polo-like Kinase 1 Inhibitor, in combination with LDAC, in Acute Myeloid Leukemia. The MTD or RP2D will be used in the Phase 2 segment of the trial to evaluate antitumor activity. May 17, 2018